Gene Mutations May Predict Risk of IBD Treatments’ Side Effects

Gene Mutations May Predict Risk of IBD Treatments’ Side Effects
Mutations in the NUDT15 gene may predict predisposition to side effects of immunosuppressants — substances that change the function of the immune system — in European patients with inflammatory bowel disease (IBD), a study suggests. The development of a test that can show whether a patient has one of the mutations might improve management of the condition. The study, "Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease," was published in the Journal of the American Medical Association (JAMA). IBD has two main forms — Crohn's disease and ulcerative colitis. Both are autoimmune disorders in which the body attacks its own microflora, resulting in inflammation of the digestive tract. Currently, there is no cure for these conditions; common treatments include immunomodulators and anti-inflammatory therapies. Thiopurines, such as azathioprine and 6-mercaptopurine, are immunomodulators commonly used in the treatment of IBD and other inflammatory and autoimmune disorders. Approximately 7% of patients develop an adverse reaction to thiopurines, called bone marrow suppression, in which the white blood cell count drops significantly, making the patient more susceptible to infections. Mutations in the TPMT gene, which holds the instructions to produce a protein that degrades toxic products of thiopurine
Subscribe or to access all post and page content.

One comment

  1. mary mccarty says:

    Please send more information on Cell therapy for Crohn’s my grandson is 20 and was diagnosed in high school senior year. He’s having a tough time with depression and controlling his diet. He goes for infusions every two months or every month not sure.

Leave a Comment

Your email address will not be published. Required fields are marked *